Abstract
Pirbenicillin is a new semisynthetic penicillin which inhibited 67% of isolates of Proteus aeruginosa tested in our laboratory, 93% of P. mirabilis, 31% of Enterobacter spp., 41% of Serratia spp., and 58% of Escherichia coli at a concentration of 6.25 μg/ml. Its activity appeared to be inoculum dependent and it was virtually inactive against 107 inocula of P. aeruginosa. It was more active than carbenicillin or ticarcillin, but less active than BL-P1654 against P. aeruginosa. Carbenicillin and ticarcillin appeared to be more active than pirbenicillin against Proteus spp., but pirbenicillin was active against some isolates of Klebsiella spp.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Acred P., Brown D. M., Knudsen E. T., Rolinson G. N., Sutherland R. New semi-synthetic penicillin active against Pseudomonas pyocyanea. Nature. 1967 Jul 1;215(5096):25–30. doi: 10.1038/215025a0. [DOI] [PubMed] [Google Scholar]
- Bodey G. P., Stewart D. In vitro studies of semisynthetic alpha-(substituted-ureido) penicillins. Appl Microbiol. 1971 Apr;21(4):710–717. doi: 10.1128/am.21.4.710-717.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodey G. P., Whitecar J. P., Jr, Middleman E., Rodriguez V. Carbenicillin therapy for pseudomonas infections. JAMA. 1971 Oct 4;218(1):62–66. [PubMed] [Google Scholar]
- Brown C. H., 3rd, Natelson E. A., Bradshaw W., Williams T. W., Jr, Alfrey C. P., Jr The hemostatic defect produced by carbenicillin. N Engl J Med. 1974 Aug 8;291(6):265–270. doi: 10.1056/NEJM197408082910601. [DOI] [PubMed] [Google Scholar]
- Rodriguez V., Bodey G. P., Horikoshi N., Inagaki J., McCredie K. B. Ticarcillin therapy of infections. Antimicrob Agents Chemother. 1973 Oct;4(4):427–431. doi: 10.1128/aac.4.4.427. [DOI] [PMC free article] [PubMed] [Google Scholar]